ClinTec International Expands US Capabilities with the Launch of New York Office and Senior Business Operations Appointment
ClinTec International
has unveiled an expansion into the US marketplace, with the launch of its New York office and the appointment of Susan Pavone, Associate Director of US Business Operations.
The expansion of US based operations through the launch of American headquarters, together with Susan Pavone’s appointment, will enable ClinTec to offer prospective US clients the chance to access global clinical research capabilities through a single partner.
President & CEO of ClinTec International, Dr Rabinder Buttar, commented: “We have established a strong presence in the international marketplace by placing clinical research staff in all key emerging, and established markets. The pharmaceutical industry is currently searching for new ways of working and delivering global solutions. ClinTec’s ability to harness global strength, coupled with local expertise, will be of great value to US pharmaceutical companies. Our new Associate Director of (US) Operations, Susan Pavone, has extensive knowledge of international clinical research and the new US facilities will prove an invaluable asset to American companies looking to tap into our globalised resources.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
